Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
About this item
Full title
Author / Creator
Honig, Lawrence S , Vellas, Bruno , Woodward, Michael , Boada, Mercè , Bullock, Roger , Borrie, Michael , Hager, Klaus , Andreasen, Niels , Scarpini, Elio , Liu-Seifert, Hong , Case, Michael , Dean, Robert A , Hake, Ann , Sundell, Karen , Poole Hoffmann, Vicki , Carlson, Christopher , Khanna, Rashna , Mintun, Mark , DeMattos, Ronald , Selzler, Katherine J and Siemers, Eric
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a randomized trial, solanezumab, a humanized monoclonal antibody against soluble amyloid, did not slow cognitive decline over a period of 80 weeks in patients with mild Alzheimer’s disease and with PET or CSF biomarkers of amyloid-related disease.
Alternative Titles
Full title
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Authors, Artists and Contributors
Author / Creator
Vellas, Bruno
Woodward, Michael
Boada, Mercè
Bullock, Roger
Borrie, Michael
Hager, Klaus
Andreasen, Niels
Scarpini, Elio
Liu-Seifert, Hong
Case, Michael
Dean, Robert A
Hake, Ann
Sundell, Karen
Poole Hoffmann, Vicki
Carlson, Christopher
Khanna, Rashna
Mintun, Mark
DeMattos, Ronald
Selzler, Katherine J
Siemers, Eric
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1991140000
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1991140000
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1705971
